Molecular biology of prostate carcinogenesis

Critical Reviews in Oncology/Hematology

Volumn 32, Issue 3, 1999, Pages 197-208

  Lara Jr , Primo N ^a   Kung, Hsing Jien ^a   Gumerlock, Paul H ^a   Meyers, Frederick J ^a  

^a Division of Hematology Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CELL ADHESION MOLECULE; GROWTH FACTOR; PROTEINASE; TELOMERASE;

CANCER GROWTH; CANCER RISK; CARCINOGENESIS; GENE OVEREXPRESSION; GROWTH REGULATION; HETEROZYGOSITY LOSS; HUMAN; METASTASIS POTENTIAL; ONCOGENE; PROSTATE CANCER; PROTO ONCOGENE; REVIEW; RISK FACTOR; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

ANIMALS; GENES, TUMOR SUPPRESSOR; HUMANS; KARYOTYPING; MALE; ONCOGENES; PROSTATIC NEOPLASMS;

EID: 0344183071     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00041-4     Document Type: Review

References (139)

1. Cancer facts and figures 1998. 1998;20-24 American Cancer Society, Atlanta, GA.
2. Ries L., Kosary C., Hankey B.F. et al. SEER cancer statistics review, 1973-1994: tables and graphs. 1997;National Cancer Institute, Bethesda, MD. NIH Publication No. 97-2789.
3. Vogelstein B., Fearon E., Kern S. et al. Allelotype of colorectal carcinomas. Science. 244:1989;207-211.
4. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
5. Knudson A.G. Hereditary cancer, oncogenes, and anti-oncogenes. Cancer Res. 45:1985;1437.
6. Lalani E., Laniado M.E., Abel P.D. Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev. 16:1997;29-66.
7. Gleason D.F. Histologic grading and clinical staging of prostatic carcinoma. Tannenbaum M. Urologic pathology: the prostate. 1997;171-197 Lea and Febringer, Philadephia.
8. Lerner S.E., Blute M.L., Zincke H. Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin. Urol. Oncol. 14(suppl 2):1996;12-21.
9. Iselin C.E., Vollmer R.E., Box J. et al. Surgical control of clinically localized prostate cancer is equivalent in African American and white males. Cancer. 83:1998;2353-2360.
10. Pretlow T.G., Nagabhusahn M., Sy M. et al. Putative preneoplastic foci in the human prostate. J. Cell. Biochem. 19(suppl):1994;224-231.
11. McNeal J.E., Bostwick D.G. Intraductal dysplasia: a premalignant lesion of the prostate. Hum. Pathol. 17:1986;64-71.
12. Mostofi F.K., Sesterhenn I.A., Davis C.J. Prostatic intraepithelial neoplasia (PIN): morphological clinical significance. Prostate. 4(suppl):1992;71-77.
13. Bostwick D.G., Brawer M.K. Prostatic intraepithelial neoplasia and early invasion in prostate cancer. Cancer. 50:1988;788-794.
14. Bostwick D.G. Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Eur. Urol. 30:1996;145-152.
15. Pylkkanen L., Makela S., Santti R. Animal models for the preneoplastic lesions of the prostate. Eur. Urol. 30(2):1996;243-248.
16. Bosland M.C. Animal models for the study of prostate carcinogenesis. J. Cell. Biochem. 16H(suppl):1992;89-98.
17. Elghany N.A., Schumacher M.C., Slattery M.L., West D.W., Lee J.S. Occupation, cadmium exposure, and prostate cancer. Epidemiology. 1(2):1990;107-115.
18. Spitz M.R., Currier R.D., Fuerger J.J. et al. Familial patterns of prostate cancer: a case control analysis. J. Urol. 146:1991;1305-1307.
19. Steinberg G.D., Carter B.S., Beaty T.H. et al. Family history and the risk of prostate cancer. Prostate. 17:1990;337-347.
20. Cannon L., Bishop D.T., Skolnick M. et al. Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Surv. 1:1982;47-49.
21. Carter B.S., Beaty T.H., Steinberg G.D. et al. Mendelian inheritance of familial prostate cancer. Proc. Nat. Acad. Sci. USA. 89:1992;3367-3371.
22. Cooney K.A., McCarthy J.D., Lange E. et al. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J. Natl. Cancer Inst. 89:1997;1893-1894.
23. Micale M.A., Mohammed A., Sakr W. et al. Cytogenetics of primary prostatic adenocarcinoma: clonality and chromosome instability. Cancer Genet. Cytogenet. 61:1992;165-173.
24. Cher M.L., Bova G.S., Moore D.S. et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 56:1996;3091-3102.
25. Lundgren R., Heim S., Mandahl N. et al. Chromosomal abnormalities are associated with unfavorable outcome in prostatic cancer patients. J. Urol. 147:1992;784-788.
26. Carter B.S., Ewing C.M., Ward W.S. et al. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc. Nat. Acad. Sci. USA. 87:1990;8751-8755.
27. Lundgren R., Mandahl N., Heim S. et al. Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes Chromosomes Cancer. 4:1992;16-24.
28. Takahashi S., Shan A., Ritland S.R. et al. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res. 55:1995;4114-4119.
29. Bandyk M.G., Zhao L., Troncoso P. et al. Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer. 9:1994;19-27.
30. Wang R.Y., Troncoso P., Palmer J.L. et al. Trisomy 7 by dual-color fluorescence in situ hybridization: a potential biological marker for prostate cancer progression. Clin. Cancer Res. 2:1996;1553-1558.
31. Kunimi K., Bergenheim U.S., Larsson I.L. et al. Allelotyping of human prostatic adenocarcinoma. Genomics. 11:1991;530-536.
32. Bergenheim U.S., Kunimi K., Collins V.P., Ekman P. Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosomes Cancer. 3:1991;215-220.
33. Macoska J., Trybus T., Sakr W. et al. Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res. 54:1994;3824-3830.
34. Emi M., Fujiwara Y., Nakajima T. et al. Frequent loss of heterozygozity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res. 5:1992;5368-5372.
35. Konig J.J., Kamst E., Hagemeijer A. et al. Cytogenetic characterization of several androgen responsive and unresponsive sublines of the human prostate carcinoma cell line LNCaP. Urol. Res. 17:1989;79-86.
36. Ittman M. Allelic loss of chromosome 10 in prostate adenocarcinoma. Cancer Res. 56:1996;2143-2147.
37. Maehama T., Dixon J.E. The tumor suppressor PTEN/MMAC1 dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-triphosphate. J. Biol. Chem. 273:1998;13375-13378.
38. Ittmann M.M. Chromosome 10 alterations in prostate adenocarcinoma. Oncol. Rep. 5(6):1998;1329-1335.
39. Natt E., Magenis R.E., Zimmer J. et al. Regional assignment of the human loci for uvomorulin (UVO) and chymotrypsinogen B (CTRB) with the help of two overlapping deletions on the long arm of chromosome 16. Cytogenet. Cell Genet. 50:1989;145-148.
40. Graff J.R., Herman J.G., Lapidus R.G. et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostatic carcinomas. Cancer Res. 55:1995;5195-5199.
41. Schalken J.A., Smit F., Bringuier P.P. et al. The role of E-cadherin mutations in bladder and prostate cancer: Is E-cadherin a classical suppressor gene? J. Urol. 155:1996;339A.
42. Giroldi L.A., Schalken J.A. Decreased expression of the intracellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. Cancer Metastasis Rev. 12:1993;29-37.
43. Isaacs W.B. Molecular genetics of prostate cancer. Cancer Surv. 25:1995;357-379.
44. Cooney K.A., Wetzel J.C., Consolino C.M., Wojno K.J. Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res. 56:1996;4150-4153.
45. Jenkins R.B., Qian J., Lieber M.M., Bostwick D.G. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in-situ hybridization. Cancer Res. 57:1997;524-531.
46. Matusik R.J., Fleming W.H., Hamel A. et al. Expression of the c-myc proto-oncogene in prostatic tissue. Prog. Clin. Biol. Res. 239:1987;91-112.
47. Gumerlock P.H., Poonamallee U.R., Meyers F.J., DeVere White R. Activated ras alleles in human carcinoma are rare. Cancer Res. 51:1991;1632-1637.
48. Moul J.W., Friedrichs P.A., Lance R.S. et al. Infrequent ras oncogene mutations in prostate cancer. Prostate. 20:1992;327-338.
49. Konishi N., Enomoto T., Buzard G. et al. K ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer. 69:1992;2293-2299.
50. Coussens L., Yang Feng T., Liao Y.C. et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 230:1985;1132-1139.
51. Gullick W.J. The role of epidermal growth factor and the c-erbB-2 protein in breast cancer. Int. J. Cancer. 5(suppl):1990;55-61.
52. Slamon D.J., Godolphin W., Jones L. et al. Studies of HER-2/neu protooncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
53. Zhau H.E., Wan D.S., Zhou J. et al. Expression of c-erb b-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol. Carcinog. 5(4):1992;320-327.
54. Kuhn E.J., Kurnot R.A., Sesterhem I. et al. Expression of cerbB2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J. Urol. 150(5):1993;1427-1433.
55. Craft N., Shostak Y., Carey M., Sawyers C. A mechanism of hormone independent prostate cancer through modulation of androgen receptor signaling by the Her2/neu tyrosine kinase. Nat. Med. 5:1999;280-285.
56. Kallakury B.V., Sheehan C., Ambros R. et al. Correlation of p34-cdc2 cyclin dependent kinase overexpression, cd44 downregulation, and Her2/neu oncogene amplification with recurrence in prostatic adenocarcinoma. J. Clin. Oncol. 16(4):1998;1302-1309.
57. Robinson D., He F., Pretlow T., Kung H.J. A tyrosine kinase profile of prostate carcinoma. Proc. Natl. Acad. Sci. USA. 93(12):1996;5958-5962.
58. Meyers R.B., Srivastava S., Oelschlager D.K., Grizzle W.E. Expression of p160 erbB-3 and p185 erbB-2 in prostate intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl. Cancer Inst. 86:1994;1140-1145.
59. Leung H.Y., Weston J., Gullick W.J., Williams G. A potential autocrine loop between heregulin-α and erbB3 receptor in human prostatic adenocarcinoma. Br. J. Urol. 79(2):1997;212-216.
60. Lin M.F., Meng T.C., Rao P.S. et al. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J. Biochem. 6:1998;5939-5947.
61. Pisters L.L., Troncoso P., Zhau H.Y.E. et al. The role of hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene, in human prostatic tumor growth. J. Urol. 149:1993;482A.
62. Zhau H.E., Pisters L., Hall M.C. et al. Biomarkers associated with prostate cancer progression. J. Cell. Biochem. 19(suppl):1994;208-216.
63. Dawson D.M., Lawrence E.G., MacLennan G.T. et al. Altered expression of RET proto-oncogene in prostatic intraepithelial neoplasia and prostate cancer. J. Natl. Cancer Inst. 90(7):1998;519-523.
64. Miyashita T., Reed J. Bcl2 oncoprotein blocks chemotherapy induced apoptosis in a human leukemia cell line. Blood. 11:1993;151-157.
65. Reed J.C. Dysregulation of apoptosis in cancer. Cancer J. Sci. Am. 4(suppl 1):1998;S8-S14.
66. Reed J.C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr. Opin. Oncol. 7:1995;541-546.
67. Kyprianou N., English H.F., Isaacs J.T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 50:1990;3748-3753.
68. Hockenberry D.M., Zutter M., Hickey W. et al. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. USA. 88:1991;6961-6965.
69. Raffo A.J., Perlman H., Chen M.W. et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 55:1995;4438-4445.
70. Colombel M., Symmans F., Gil S. et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol. 143:1993;390-400.
71. McDonnell T.J., Troncoso P., Brisbay S.M. et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52:1992;6940-6944.
72. Krajewski S., Krajewska M., Shabaik A. et al. Immunohistochemical determination of in-vivo distribution of bax, a dominant inhibitor of bcl-2. Am. J. Pathol. 145:1994;1323-1336.
73. Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1996;1253-1255.
74. Gao X., Porter A.T., Honn K.V. Involvement of multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer: therapeutic implications. Adv. Exp. Med. Biol. 407:1997;41-53.
75. Hopkin K. Survival of the fittest cells. J. Natl. Inst. Health Res. 8:1996;37-41.
76. Weinberg R.A. Tumor suppressor genes. Science. 254:1991;249-270.
77. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. P53 mutations in human cancers. Science. 253:1991;49-53.
78. Bookstein R. Tumor suppressor genes in prostatic oncogenesis. J. Cell. Biochem. 19(suppl):1994;217-223.
79. Wertz I.E., Deitch A.D., Gumerlock P.H. et al. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum. Pathol. 27(6):1996;573-580.
80. Gumerlock P.H., Chi S.G., Shi X.B. et al. P53 abnormalities in primary prostate cancer: single strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J. Natl. Cancer Inst. 89(1):1997;66-71.
81. Navone N.M., Troncoso P., Pisters L.L. et al. P53 accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst. 85:1993;1657-1669.
82. Effert P.J., McCoy R.H., Walther P.J. et al. P53 gene alterations in human prostate carcinoma. J. Urol. 150:1993;257-261.
83. Chi S.G. et al. P53 in prostate cancer: frequent expressed transition mutations. J. Natl. Cancer Inst. 12:1994;926-933.
84. Meyers F.J., Gumerlock P.H., Chi S.-G. et al. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer. 83(12):1998;2534-2539.
85. Myers R.B., Oelschlager D., Srivastava S., Grizzle W.E. Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate. 25:1994;243-248.
86. Tricoli J.V., Gumerlock P.H., Yao J.L. et al. Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes Chromosomes Cancer. 15:1996;108-114.
87. Mack P.C., Chi S.G., Meyers F.J. et al. Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade. Prostate. 34(2):1998;145-151.
88. Fearon E.R., Cho K.R., Nigro J.M. et al. Identification of a chromosome 18q gene that is altered in colorectal carcinoma. Science. 247:1990;49-56.
89. Gao X., Honn K.V., Grignon D. et al. Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res. 53:1993;2723-2727.
90. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK. Nature. 366:1993;704-707.
91. Chi S.G., deVere White R.W., Muenzer J.T., Gumerlock P.H. Frequent alteration of CDKN2 (p16/MTS1) expression in human primary prostate carcinomas. Clin. Cancer Res. 3:1997;1887-1889.
92. Vlietstra R.J., van Alewijk D.C., Hermans K.G. et al. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 58:1998;2720-2723.
93. Cairns P., Okami K., Halchmi S. et al. Frequent inactivation of the PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57:1997;4997-5000.
94. Giri D., Ittmann M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate cancer. Hum. Pathol. 30:1999;419-424.
95. Dong J.T., Suzuki H., Pin S.S. et al. Down regulation of KAI1 metastasis suppressor gene during progression of human prostatic cancer infrequently involves gene mutation or loss. Cancer Res. 56:1996;4387-4390.
96. Gao A.C., Lou W., Dong J.T., Isaacs J.T. CD44 is a metastasis suppressor gene for prostate cancer located on human chromosome 11p13. Cancer Res. 57:1997;846-849.
97. Luu H.H., Zagaja G.P., Dubauskas Z. et al. Identification of a novel metastasis suppressor gene on human chromosome 12. Cancer Res. 58:1998;3561-3565.
98. Tilley W.D., Marcelli M., Wilson J.D., McPaul M.J. Characterization and expression of a cDNA encoding the human androgen receptor. Proc. Natl. Acad. Sci. USA. 86:1989;327-331.
99. Caskey C.T., Pizzuti A., Fu Y.H., Fenwick R.G., Nelson D.L. Triplet repeat mutations in human disease. Science. 256:1992;784-788.
100. Chamberlain N.L., Driver E.D., Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 22:1994;3181-3186.
101. Giovannucci E., Stampfer M.J., Krithivas K., Brown M., Brufsky A., Talcott J. et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA. 94:1997;3320-3323.
102. Newmark J.R., Hardy D.O. et al. Androgen receptor gene mutations in human prostate cancer. Proc. Natl. Acad. Sci. USA. 89:1992;6319-6323.
103. Tilley W.D., Wilson C.M., Marcelli M., McPhaul M.H. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res. 50:1990;5382-5386.
104. Visakorpi T., Hyytinen E., Koivisto P. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9:1995;401-406.
105. Klocker H., Culig Z., Hobisch A. et al. Androgen receptor alterations in prostatic carcinoma. Prostate. 25:1994;266-273.
106. Tilley W.D., Buchanan G., Hickey T.E., Bentel J.M. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res. 2:1996;277-285.
107. Gaddipati J.P., McLeod D.G., Heidenberg H.B. et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 54:1994;2861-2864.
108. De Vere White R., Meyers F., Chi S.G. et al. Human androgen receptor expression in prostate cancer following androgen ablation. Eur. Urol. 31(1):1997;1-6.
109. Taplin M., Bubley G., Shuster T. et al. Mutation of the androgen receptor gene in metastatic androgen independent prostate cancer. N. Engl. J. Med. 332:1995;1393-1398.
110. Hobisch A., Culig Z., Radmayr C. et al. Distant metastases from prostate carcinoma express androgen receptor protein. Cancer Res. 55:1995;3068-3072.
111. Allsopp RC, Vaziri H, Patterson J et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA. 89:1992;10114-10118.
112. Bacchetti S., Counter C.M. Telomerase: a key to cell immortality. Int. J. Oncol. 7:1995;423-432.
113. Zhang W., Kapusta L.R., Slingerland J.M., Klotz L.H. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res. 58:1998;619-621.
114. Byrne R., Leung H., Neal D.E. Peptide growth factors in the prostate as mediators of stromal epithelial interactions. Br. J. Urol. 77:1996;627-633.
115. Dong J.T., Isaacs W.B., Isaacs J.T. Molecular advances in prostate cancer. Curr. Opin. Oncol. 9:1997;101-107.
116. Polyak K. Negative regulation of cell growth by TGF-B. Biochem. Biophys. Acta. 1242:1996;185-199.
117. Kim I.Y., Ahn H.J., Zelner D.J. et al. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin. Cancer Res. 2:1996;1255-1261.
118. Truong L.D., Kadmon D., McCune B.K. et al. Association of transforming growth factor beta 1 with prostate cancer: an immunohistochemical study. Hum. Pathol. 24:1993;4-9.
119. Thompson T.C. Growth factors and oncogenes in prostate cancer. Cancer Cells. 2:1990;345-354.
120. Davies P., Eaton C. Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate. Prostate. 14:1989;123-132.
121. Traish A.M., Wortiz H.H. Prostatic epidermal growth factor receptors and their regulation by androgens. Endocrinology. 121:1987;1461-1467.
122. Wilding G., Valverius E., Knabbe C., Gelmann E.P. Role of transforming growth factor alpha in human prostate cancer cell growth. Prostate. 15:1989;1-12.
123. Lloyd S.N., Brown L.L., Leake R.E. Transforming growth factor alpha expression in benign and malignant human prostatic disease. Int. J. Biol. Markers. 7:1992;27-34.
124. Culig Z., Hobich A., Cronauer M.V. et al. Androgen receptor activation in prostatic tumor cell lines by insulin like growth factor I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54:1994;5474-5478.
125. Iwamura M., Sluss P.M., Casamento J.B. et al. Insulin like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate. 22:1993;243-252.
126. Chan J.M., Stampfer M.J., Giovannucci E. et al. Plasma insulin like growth factor I and prostate cancer risk: a prospective study. Science. 279:1998;556-563.
127. Jarrard D.F., Bussemakers M.J.G., Bova G.S., Isaacs W.B. Regional loss of imprinting of the insulin like growth factor II occurs in human prostate tissues. Clin. Cancer Res. 1:1995;1471-1478.
128. Giri D., Ropiquet F., Ittmanm M. Alterations in expression of basic fibroblast growth factor (FGF)2 and its receptor FGFR-1 in human prostate cancer. Clin. Cancer Res. 5:1999;1063-1071.
129. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G. Cancer angiogenesis and metastasis: an imbalance of positive and negative regulation. Cell. 64:1991;327-336.
130. Cress A.E., Rabinovitz I., Zhu W., Nagle R.B. The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev. 14(3):1995;219-228.
131. Graff J.R., Herman J.G., Lapidus R.G. et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55:1995;5195-5199.
132. Umbas R., Schalken J.A., Aalders T.W. et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 52:1992;5104-5109.
133. Ross J.S., Figge H.L., Bui H.X. et al. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. Mod. Pathol. 7:1994;835-841.
134. Giroldi L.A., Schalken J.A. Decreased expression of the intracellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. Cancer Metastasis Rev. 12:1993;29-37.
135. Richmond P.J., Karayiannakis A.J., Nagafuchi A. et al. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res. 57:1997;3189-3193.
136. Stearns M.E., Wang M. Immunoassays of the metalloproteinase (MMP-2) and tissue inhibitor of metalloproteinase (TIMP1 and 2) levels in non-invasive and metastatic PC-3 clones: effects of taxol. Oncol. Res. 6:1994;195-201.
137. Pajouh M.S., Nagle R.B., Breathnach R. et al. Expression of metalloproteinase genes in human prostate cancer. J. Cancer Res. Clin. Oncol. 117:1991;144-150.
138. Baker T., Tickle S., Wasan H. et al. Serum metalloproteinases and their inhibitors: markers for malignant potential. Br. J. Cancer. 70:1994;506-512.
139. Sandberg A.A. Chromosomal abnormalities and related events in prostate cancer. Hum. Pathol. 23:1992;368-380.